From a clinical standpoint, the message is clear: - Yes to metabolic monitoring - Yes to awareness of glycemic risk - But no to avoiding statins out of fear of diabetes, especially in patients at high cardiovascular risk The real question isnt: Do statins cause diabetes? but rather: Does cardiovascular benefit outweigh metabolic risk? And once again, the answer is: yes
No math is required
To answer that question, McDonald and her colleagues are working to launch a multisite clinical trial examining whether GLP-1 medications can lower breast cancer incidence in women considered high risk, including some with a previous history of breast cancer
The serene green, the fogged glass, and the pump top that actually works
Similarly, in diabetic rats, Met and silymarin treatment improved sperm parameters, sperm DNA integrity, seminiferous tubule diameter, germinal epithelium thickness, and testicular histopathology
Ni Y, Eng C